ICER issues final report and policy recommendations on JAK inhibitors for rheumatoid arthritis

ICER

9 January 2020 - Despite upadacitinib reaching common thresholds for cost-effectiveness when compared to adalimumab, the independent appraisal committee’s votes on upadacitinib’s long-term economic value were split between “low” and “intermediate” due to concerns about the generalisability of the clinical data to patients in the real world.

The Institute for Clinical and Economic Review today released a Final Evidence Report and Report-at-a-Glance assessing the comparative clinical effectiveness and value of JAK inhibitors for treating rheumatoid arthritis. 

These therapies include upadacitinib (Rinvoq, AbbVie), tofacitinib (Xeljanz, Pfizer), and baricitinib (Olumiant, Eli Lilly), as compared to either placebo or adalimumab (Humira, AbbVie).

Read ICER Announcement

Michael Wonder

Posted by:

Michael Wonder